-
Mashup Score: 0The Role of Surgery in Stage I Small Cell Lung Cancer: A National VA database analysis - 1 year(s) ago
Background: Historically, limited stage Small Cell Lung Cancer (SCLC) has been treated with concurrent chemoradiation (CRT). While current NCCN guidelines recommend consideration of lobectomy in node-negative cT1-T2 SCLC, data regarding the role of surgery in very limited SCLC is lacking.Methods: Data from the National VA Cancer Cube were compiled. A total of 1,028 patients with pathologically…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Short report of a phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM) - 1 year(s) ago
Malignant pleural mesothelioma (MPM) is a disease for which there remains an unmet need for better therapeutic options. Nintedanib is an oral multikinase inhibitor impacting VEGF, FGF, PDGFR, and other kinase activity such as TGFß signaling pathways. We conducted a phase II trial of nintedanib in patients with recurrent MPM.
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Phase II study of nintedanib in patients with relapsed mesothelioma @ClinicalLung. In 20 pts, no responses. mPFS 1.8m and mOS 4.2m. Reasonably well tolerated but no clear signal here. #MPM https://t.co/ZBQpEbJCmn
-
-
Mashup Score: 1
Substantial therapeutic advancements have been made in identifying and treating activating mutations in advanced non-small cell lung cancer (NSCLC); however, resistance to epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) inhibitors remains common with current targeted therapies. Amivantamab, a fully human bispecific antibody targeting EGFR and MET, is…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Review article @ClinicalLung on amivantamab, the EGFR-MET bispecific approved for #EGFR exon 20 insertion NSCLC and its different potential mechanisms of action (ligand blocking, receptor degradation, ADCC, trogocytosis). https://t.co/CxTxHbPr8V
-
-
Mashup Score: 0A multi-center retrospective chart review of clinical outcomes among patients with KRAS G12C mutant non-small cell lung cancer - 1 year(s) ago
On May 28, 2021, the United States Food and Drug Administration (FDA) granted accelerated approval to sotorasib for second-line or later treatment of patients with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC). This was the first FDA-approved targeted therapy for this patient population. Due to a paucity of real world data describing clinical outcomes in…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Retrospective report @ClinicalLung on real world outcomes in pts with #KRAS G12C NSCLC from #ATOMIC consortium. First-line rwPFS 9.3m and 2nd line rwPFS with docetaxel-based therapy 4.6m. Outcomes worse with STK11 co-mutation. https://t.co/Swrqqb29oN
-
-
Mashup Score: 1Liquid Biopsy Screening for Early Detection of Lung Cancer: Current State and Future Directions - 1 year(s) ago
Liquid biopsy (LB) is a clinically utilized to detect minute amounts of genetic material or protein shed by cancer cells, most commonly cell free DNA (cfDNA), as a non-invasive precision oncology tool to assess genomic alterations to guide cancer therapy or to detect the persistence of tumor cells after therapy. LB is also being developed as a multi-cancer screening assay1. Although blood-based…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Nice review @ClinicalLung of liquid biopsy as a lung cancer screening tool. While low dose CT screening is our best tool for early detection and reduces lung cancer mortality, in the future, blood based testing will hopefully be a powerful complement. https://t.co/A2ktZ7KwHR
-
-
Mashup Score: 0Anaplastic Lymphoma Kinase (ALK) Positive Neuroendocrine Tumor of Lung With Favorable Response to Alectinib (ALK inhibitor) - 1 year(s) ago
Anaplastic lymphoma kinase (ALK) genetic alterations are commonly associated with and screened for in non-small cell lung carcinoma. However, the incidence and significance of ALK mutations in neuroendocrine lung tumors are poorly defined. This is a case of a 45-year-old female who presented with confusion, fall, and weakness. Investigation showed primary lung mass, two intracranial lesions, and…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Case @ClinicalLung of a patient with high-grade neuroendocrine lung cancer (mixed SCLC and LCNE) with an #ALK fusion. Treated with alectinib for 5+ years. In my practice, neuroendocrine tumors are less responsive but encouraging to see a good outcome. https://t.co/WPuTWXsHKj
-
-
Mashup Score: 11
Leptomeningeal metastasis (LM) is a catastrophic complication of advanced lung adenocarcinoma (LUAD) with a morbidity of 3–5%, and its incidence has been increasing in recent years due to the extensive appliance of molecular targeted therapy.1,2 Related clinical symptoms, such as severe headaches, refractory nausea and vomiting, make patients anguished. Tyrosine kinase inhibitors (TKIs) are the…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Phase I study of intrathecal pemetrexed for pts (n=23) with lung adeno and leptomeningeal metastasis @ClinicalLung. RR 44%, DCR 83%, mPFS 6.3m, mOS 9.5m. Dose is 30mg pemetrexed d1 and d8 q21d. Ommaya reservoir led to higher concentrations than serial LP. https://t.co/VTN4kQ7x7n
-
-
Mashup Score: 0Trends in Stage I Lung Cancer - 1 year(s) ago
The American Cancer Society (ACS) estimates that lung cancer will account for 236,740 new cases and 130,180 deaths for the year 2022, making it the most common cause of cancer death in the United States.1 One of the main reasons for the poor outcomes in lung cancer is the high percentage of patients with advanced stage at diagnosis, for which the treatment is mostly palliative. Nevertheless, the…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Incidence of stage I lung cancer increased between 2010-2017 #LCSM https://t.co/iEKG6cAK5S
-
-
Mashup Score: 0What Goals Do Patients and Oncologists Have When Starting Medical Treatment for Metastatic Lung Cancer? - 1 year(s) ago
MicroabstractIt is unknown what treatment goals patients and oncologists have before starting systemic treatment. In total, 266 patients with metastatic lung cancer and their prescribing oncologists (n = 23) were included. Patients and oncologist set quality of life, life prolongation, decreased tumor, and cure as treatment goals, but concordances of treatment goals were low. Clear communication…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
In a recent study evaluating goals of patients with #metastaticlungcancer, both QOL and life prolongation were reported first among treatment goals (45%), followed by decreasing tumor size (39%) and cure (19%) #lungcancer #oncology 8/10 Link: https://t.co/lG5nvSEx1P https://t.co/w114xd36HF
-
-
Mashup Score: 7
Substantial therapeutic advancements have been made in identifying and treating activating mutations in advanced non-small cell lung cancer (NSCLC); however, resistance to epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) inhibitors remains common with current targeted therapies. Amivantamab, a fully human bispecific antibody targeting EGFR and MET, is…
Source: Clinical Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Nice overview of the EGFR-MET bispecific antibody amivantamab @ClinicalLung reviewing its structure and potential mechanisms of action (inhibition of EGFR and/or MET ligand binding, receptor degradation, ADCC, trogocytosis) and early clinical data. #LCSM https://t.co/CxTxHbPr8V
-
Retrospective report @ClinicalLung from the VA system showing better outcomes with surgery than CRT for pts with stage I #SCLC. But major of selection bias to even consider surgery. And need to know how many recurred shortly after surgery and went to CRT? https://t.co/mXwKiYaMIo